c
 



  

Established in 1990, Strides is one of India¶s leading integrated manufacturer and exporter of As pharma companies reach out to enhance their strength and competitiveness, their key requirement
finished pharmaceutical dosage forms ± both branded and generic. We are a significant global is for a synergistic partner. A partner who is truly global in skill sets, R&D, manufacturing practices and
player in soft gelatin capsules and sterile parenterals with quality standards that meet the most in attitude and vision.
stringent regulated market standards.

At Strides, we are all that and more ± because we believe in ³Leadership through Partnering´. We are
We have 13 world class plants in India, Singapore, Brazil, Mexico, Poland and Italy offering partners to more than 10 of the world¶s top 50 pharma majors in Australia, South Africa, Europe, and
our partners the advantage of multi-locational product sourcing. USA.

We are among the world¶s top 5 soft gelatin capsule manufacturers.
Our R&D interweave offers end-to-end solutions from concept to delivery and a go -to-market
pipeline of products that are patent non -infringing formulations across dosage forms.
Our ethos centers around customer focus and rapid response. Over the last decade, w e have
systematically strengthened our capabilities in understanding and aligning ourselves with our partner¶s
needs. Through product innovation, manufacturing, operational flexibilities and leveraging our IP in
formulation technologies, we have significantly enhanced our partner¶s marketing leadership.

We have marketing presence in 55 countries. This broad network facilitates partnering with
global organisations ranging from Unicef, UNDP, Global TB Drug Facility, The Clinton
Foundation to European and American pharma giants and even private labelers and
distribution chains.

In addition, we undertake contract R & D and manufacture of pharmaceutical dosage forms.



c


In just over a decade, Strides Arcolab has grown phenomenally to become one of India¶s largest
exporters of pharmaceutical formulations. As a group, our annual sales approach $100 million in
2003 - 2004. Strategically, we have re-oriented our positioning to capture a greater share of the
regulated markets. The group ethos is based on ³leadership through partnering´. Our foray into the
regulated markets is in partnership with pharma majors. We have also launched global initiatives
to promote products for HIV/AIDS, tuberculosis and malaria. Our R&D department is being
expanded to further enhance quality driven processes and drug development capabilities.
We manufacture a very wide spectrum of ethical pharmaceutical products, OTC products and
nutraceuticals . Our range of dosage forms is equally impressive ± soft gel capsule, hard gel
capsules, tablets and dry and wet injectables. Last but not least are our awards and accreditations
±MHRA, MCC, and TGA.
Our top management has more than a hundred years of coll ective experience in the
pharmaceutical industry.


c




   
@

 

Our manufacturing platform is global in scale and compliance. We are among the few fully
integrated players in soft gels and steriles. Our quality standards meet the most stringent We are one of the world¶s top 5 soft gel manufacturers with five dedicated lines in our ODF facility
regulated market requirements. Strategic sourcing of APIs and high quality, cost effective in Bangalore, India. .. More..
manufacturing give our partners and us a competitive edge.
@

We have 13 world class plants in India, Singapore, Brazil, Mexico, Poland and Italy, all conform ing The facility for non ceph non beta lactam steriles is approved by US FDA, MHRA, TGA, MCC and
ANVISA. The facility for beta lactams is approved by MHRA, TGA, MCC and ANVISA .. More
to W HO¡¯s cGMP guidelines. Our oral dosage forms plant in Bangalore is approved by MHHRA,
TGA, MCC, ANVISA and a host of regulatory authorities from countries in Asia and Africa. This
plant is also pre -qualified by W HO for manufacture of HIV/ AIDS and anti TB drugs and is
approved by USFDA under PEPFAR.

We have dedicated facilities for the manufacture of cephalosporins, beta lactams and anti TB
products (colored).

Our dosage forms range includes tablets, capsules, soft gelatin capsules, parenterals and semi-
solids.


K


Our R&D centre at Bangalore, @ c
@



 


  is the global Key activities at STAR include identification and characterization of the reference drug, information on drug product, patent and regulatory review,
pharmaceutical research centre of the Strides pre-formulation studies, formula development, analytical method development, analytical method validation, packaging development, scale up from
Group where 200 top notch researchers are lab scale, stability studies, bioequivalence studies, preparation and submission of technical dossier.
breaking new ground in pharmaceutical
research.
Dosage form capabilities at STAR include tablets, soft gel capsules, hard gel capsules, lyophilized injectables, dry powder p arenterals, liquid
injectables, ointments and liquids.




= Clinical supplies manufacturing

= Process development

= Analytical services

= Packaging development

= Microbiological testing




c
!@
c@

!"! !c !#

$!#%
c! @

&cc!c

We are a significant global player in the international market for quality generics to fight HIV/ AIDS, We have a technical and marketing alliance with Sandoz for supply of anti TB products to the
TB and malaria. Global TB Drug Facility. Our ARVs, anti TB products and ACTs are distributed to more than 27
countries worldwide.

The oral dosage forms facility at Bangalore is pre -qualified by W HO for manufacture of anti-
retroviral drugs (ARVs) and anti TB products and by the US FDA for ARVs under the PEPFAR CONTACT US
programme. 7 ARVs are pre-qualified by WHO and 9 have been granted tentative approval by the Aloka.sengupta@stridesarco.com
US FDA.

h

Our focus on globally competitive quality and efficient deliveries has earned us a significant
presence in 50 countries worldwide with leading generics and branded companies. We offer a
wide range of products in all main dosage forms. All our products conf orm strictly to customer
specifications and those laid down by USP, BP and other leading pharmacopoeia. Innovation is a
key part of our offer and we constantly carry out product development and customisation. We
provide complete support documentation.
To meet the specific needs of various ministries of health, technical dossiers are provided along
with Site Market Files. Real time and Accelerated Stability Studies, as well as dissolution profiles
are routinely available.
A specialised team supervises the production of each batch to ensure compliance with current
good manufacturing practices. At Strides, µQuality¶ pervades all areas of our operations. Evident
from the ISO 9001, GMP and GLP Accreditations held by our plants, labs and the numerous
quality awards we have won